Share

IIR document

An original freeze-drying cycle design for a temperature sensitive molecule.

Author(s) : LHOSPICE F.

Summary

IPH1101/BrHPP is a new chemical entity and acts as an agonist of T Lymphocytes VG9D2. IPH1101 is currently tested in phase II clinical trials in some cancer indications. IPH1101 is a water soluble drug substance, highly hygroscopic. The drug substance is unstable in aqueous solution, and is sensitive to moisture content and temperature. Therefore IPH1101 has been formulated as a freeze-dried product (IPH1101 200 mg). The first freeze-drying cycle design had been developed for phase I clinical studies, with a "classical" temperature slope for each step. Unfortunately, this freeze-drying cycle didn't supply robust results; i.e. a part of IPH1101 drug product batch (up to 30%) must be removed due to a non conventional aspect. Therefore a most advanced knowledge on IPH1101 low temperature behaviour has been needed and a new approach to design freeze-drying cycle has been setup to supply clinical trials with pharmaceutically acceptable drug product.

Available documents

Format PDF

Pages: 2007-3

Available

  • Public price

    20 €

  • Member price*

    Free

* Best rate depending on membership category (see the detailed benefits of individual and corporate memberships).

Details

  • Original title: An original freeze-drying cycle design for a temperature sensitive molecule.
  • Record ID : 2008-2756
  • Languages: English
  • Source: New Ventures in Freeze-Drying
  • Publication date: 2007/07

Links


See other articles from the proceedings (12)
See the conference proceedings

Indexing